Genetic and Evolutionary Analyses of the Human Bone Morphogenetic Protein Receptor 2 (BMPR2) in the Pathophysiology of Obesity by Schleinitz, Dorit et al.
Genetic and Evolutionary Analyses of the Human Bone
Morphogenetic Protein Receptor 2 (BMPR2) in the
Pathophysiology of Obesity
Dorit Schleinitz
1, Nora Klo ¨ting
2, Yvonne Bo ¨ttcher
2, Sara Wolf
2, Kerstin Dietrich
1, Anke To ¨njes
2,3, Jana
Breitfeld
1, Beate Enigk
1, Jan Halbritter
2, Antje Ko ¨rner
4, Michael R. Scho ¨n
5, Jost Jenkner
5, Yu-Hua Tseng
6,
Tobias Lohmann
7, Miriam Drebler
7, Michael Stumvoll
2, Matthias Blu ¨her
2*, Peter Kovacs
1*
1Interdisciplinary Center for Clinical Research, University of Leipzig, Leipzig, Germany, 2Department of Medicine, University of Leipzig, Leipzig, Germany, 3Coordination
Centre for Clinical Trials, University of Leipzig, Leipzig, Germany, 4University Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany, 5Municipal
Clinic Karlsruhe, Clinic of Visceral Surgery, Karlsruhe, Germany, 6Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States of America,
7Municipal Clinic, Dresden, Germany
Abstract
Objective: Human bone morphogenetic protein receptor 2 (BMPR2) is essential for BMP signalling and may be involved in
the regulation of adipogenesis. The BMPR2 locus has been suggested as target of recent selection in human populations.
We hypothesized that BMPR2 might have a role in the pathophysiology of obesity.
Research Design and Methods: Evolutionary analyses (dN/dS, Fst, iHS) were conducted in vertebrates and human
populations. BMPR2 mRNA expression was measured in 190 paired samples of visceral and subcutaneous adipose tissue.
The gene was sequenced in 48 DNA samples. Nine representative single nucleotide polymorphisms (SNPs) were genotyped
for subsequent association studies on quantitative traits related to obesity in 1830 German Caucasians. An independent
cohort of 925 Sorbs was used for replication. Finally, relation of genotypes to mRNA in fat was examined.
Results: The evolutionary analyses indicated signatures of selection on the BMPR2 locus. BMPR2 mRNA expression was
significantly increased both in visceral and subcutaneous adipose tissue of 37 overweight (BMI.25 and ,30 kg/m
2) and 80
obese (BMI.30 kg/m
2) compared with 44 lean subjects (BMI,25 kg/m
2)( P,0.001). In a case-control study including lean
and obese subjects, two intronic SNPs (rs6717924, rs13426118) were associated with obesity (adjusted P,0.05). Combined
analyses including the initial cohort and the Sorbs confirmed a consistent effect for rs6717924 (combined P=0.01) on
obesity. Moreover, rs6717924 was associated with higher BMPR2 mRNA expression in visceral adipose tissue.
Conclusion: Combined BMPR2 genotype-phenotype-mRNA expression data as well as evolutionary aspects suggest a role of
BMPR2 in the pathophysiology of obesity.
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Introduction
Despite recent advances achieved by genome wide association
studies [1–3], the genetic factors contributing to the development
of obesity are still elusive. The prevalence of obesity has increased
particularly during the past 50 years. Since it is rather unlikely that
human genotypes changed significantly during this period, it was
probably the advent of Western lifestyle and unrestricted food
availability that caused this dramatic increase. A popular theory to
explain this observation is the ‘‘thrifty genotype’’ hypothesis [4]
proposing that humans with a genetically increased capacity to
store energy had an evolutionary advantage, since they were more
likely to survive periods of food scarcity. In modern societies with
easy access to high-caloric food and very little physical activity this
former advantage is turned into its reverse and results in obesity.
Although the hypothesis has been widely accepted, a clear
approach to identify ‘‘thrifty’’ genes has not yet been postulated.
However, the availability of high density single nucleotide
polymorphism (SNP) genotyping arrays as well as rapidly
emerging bioinformatics tools offer a possibility to reveal selective
forces on loci dispersed throughout the genome. Employing these
approaches, bone morphogenetic protein receptor 2 gene
(BMPR2) was suggested as one of the potential targets of recent
selection in European populations [5].
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transforming growth factor-b (TGF-b) superfamily and are involved
in the control of multiple key steps of embryonic development and
differentiation [6–8]. BMPs are involved in adipocyte development,
including adipose cell fate determination, differentiation of commit-
ted preadipocytes, and function of mature adipocytes [9]. The BMP
signalling requires the formation of heteromeric complexes of BMP
type 1 (BMPR1) and type 2 receptors (BMPR2) [10–12]. BMP
binding either to a single receptor type subunit followed by the
recruitment of the second subunit or to a pre-existing loose complex
of both receptor types, activates two downstream signalling cascades:
1) SMAD proteins or 2) p38 mitogen activated protein kinase
(p38MAPK) pathways [13]. Through their intracellular mediators
(SMAD proteins) BMPs can trigger mesenchymal stem cells to enter
the adipogenic and/or osteogenic lineage while preventing commit-
ment into the myogenic lineage [14]. BMP2/4 induce white fat
differentiation and BMP7 specify brown adipogenesis [15]. Since
BMPR2 can bind both BMP2/BMP4 and BMP7 to activate the
intracellular cascade involving SMAD intracellular signalling
mediators [16], it might affect both the white and the brown
adipogenesis. Also, over-expression of constitutively active BMP
receptor 1A or 1B induces the commitment of C3H10T1/2 stem
cells into adipocytes even in the absence of BMP2/4 [17]. We could
recently show that BMPR1A mRNA expression in both visceral and
subcutaneous adipose tissue as well as genetic variants in this gene
strongly correlated with obesity and its related traits [18]. BMPR2, a
serine threonine kinase located on chromosome 2q33-q34, is
responsible for the trans-phosphorylation of BMPR1, further
suggesting BMPR2 as candidate gene for obesity.
Here, we initiated studies searching for signatures of selection
for BMPR2 in vertebrates and human populations. We analysed
the coding region of BMPR2 orthologs with the Phylogenetic
Analysis by Maximum Likelihood (PAML). Furthermore, we used
Haplotter/PhaseII database to screen for selection patterns within
the BMPR2 locus including intronic regions. Since BMPR2 is also
a plausible obesity candidate gene, we searched for evidence
supporting the ‘‘thrifty gene’’ hypothesis by investigating its
potential role in the pathophysiology of human obesity. We
measured the expression of BMPR2 mRNA in paired samples of
human visceral and subcutaneous adipose tissue in subjects who
had undergone detailed metabolic testing. To determine whether
genetic variants in the BMPR2 are related to adipose tissue
BMPR2 mRNA expression and to the obese human phenotype, we
sequenced the BMPR2 and evaluated the association between
representative variants and obesity related traits in two indepen-
dent Caucasian cohorts from Germany.
Methods
Study subjects
Ethics Statement. All studies were approved by the ethics
committee of the University of Leipzig and all subjects gave written
informed consent before taking part in the study.
Leipzig cohort. A total of 930 patients with type 2 diabetes
(T2D) and 900 non-diabetic subjects recruited at the University
Hospital in Leipzig (Germany) were included in the study. Healthy
subjects included 288 males and 612 females (mean age 49614
years; mean BMI 28.765.7 kg/m
2; mean WHR 0.9460.17; mean
fasting plasma glucose 5.2960.57 mmol/l; mean fasting plasma
insulin 1246228 pmol/l). Patients with T2D included 475 males
and 455 females (mean age 64611 years; mean BMI
29.765.4 kg/m
2) (data are given as arithmetic means6SD). In
addition, oral glucose tolerance test (OGTT) and fasting plasma
insulin measurements were performed in all non-diabetic subjects
as previously described elsewhere [19]. In a subgroup of 374 non-
diabetic subjects, insulin sensitivity was assessed with euglycemic-
hyperinsulinemic clamps and plasma leptin and adiponectin
measurements were carried out.
Tissue studies. Paired samples of visceral and subcutaneous
adipose tissue were obtained from a subgroup of 190 Caucasian
men (N=91) and women (N=99), who underwent open
abdominal surgery (described in detail elsewhere) [19]. The age
ranged from 16 to 99 years and body mass index from 21 to
55 kg/m
2. In these subjects, in addition to above mentioned
clinical parameters, abdominal visceral and subcutaneous fat area
was calculated using computed tomography scans at the level of
L4-L5 and percentage body fat was measured by dual-energy X-
ray absorptiometry (DEXA).
Assays and measures of obesity and glucose
metabolism. Fasting plasma insulin was measured with an
enzyme immunometric assay for the IMMULITE automated
analyser (Diagnostic Products Corporation, Los Angeles, CA,
USA). Plasma leptin levels were assessed by radioimmunoassay
(Linco Research, St. Charles, Mo, USA). The OGTT was
performed after an overnight fast with 75 g standardized glucose
solution (Glucodex Solution 75 g; Merieux, Montreal, Canada)
and insulin sensitivity was assessed with the euglycemic-
hyperinsulinemic clamp method as described elsewhere [20;21].
Sorbs cohort. The cohort was derived from the self-contained
Sorbs population in Eastern Germany. The Sorbs represent a
population of Slavonic origin who lived in ethnic isolation among
the Germanic majority during the past 1,100 years. Today, the
Sorbian-speaking, Catholic minority comprises approximately
15,000 full-blooded Sorbs resident in about ten villages in rural
Upper Lusatia (Oberlausitz), Eastern Saxony [22]. Extensive
phenotyping included standardised questionnaires for past
medical history and family history, collection of anthropometric
data (weight, height, WHR) and OGTT (diabetes definition
according to the ADA criteria) [23]. Insulin was measured with
the AutoDELFIAHInsulin assay (PerkinElmer Life and Analytical
Sciences, Turku, Finland). Nine hundred twenty five Sorbs (740
subjects with normal glucose tolerance (NGT), 79 subjects with
impaired glucose tolerance (IGT) and 106 cases with T2D; 542
females, 383 males) were available for the present study (mean age
48616 years; mean BMI 27.064.9 kg/m
2; mean WHR
0.8760.10; mean fasting plasma glucose 5.5461.18 mmol/l;
mean fasting plasma insulin 40.7627.4 pmol/l).
Evolutionary analyses
We analysed patterns of evolution at the codon level across the
BMPR2 phylogeny (Figure S1A). The non-synonymous to synon-
ymous substitution rate ratio (v=dN/dS) of 36 BMPR2 orthologs
(http://www.ensembl.org, http://www.ncbi.nlm. nih.gov/gene;
Figure S1A,B) was estimated by maximum likelihood methods
[24] using the CODEML program (PAML4a package) [25;26]. In
addition, phased (PHASE version 2.1) [27;28] SNP data of the
HapMap populations (Utah residents with ancestry from northern
and western Europe (CEU), Yoruba in Ibadan; Nigeria (YRI), Han
Chinese in Beijing, China (CHB), Japanese in Tokyo, Japan (JPT))
were analysed for signatures of selection with DnaSP (version
5.00.03) [29], Sweep 1.8.1 and the Haplotter/PhaseII (http://hg-
wen.uchicago.edu/selection/haplotter.htm). Provided are popula-
tion genetic measures which comprises the fixation index (Fst) and
standardized integrated haplotype score (iHS) [5].
Analysis of human BMPR2 mRNA expression
Human BMPR2 expression was measured by quantitative real-
time RT-PCR using SYBR Green methodology and fluorescence
BMPR2 and Obesity
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Biosystems, Darmstadt, Germany) as described in detail elsewhere
[19]. The following primers were used: human BMPR2 (NCBI
accession no NM_001204.5) 59 CTTTACTGAGAATTTTC-
CACCTCCTG 39 (sense) and 59 GCCAAAGCAATGATTAT
TGTCTCATC 39 (antisense). Human BMPR2 mRNA expression
was calculated relative to the mRNA expression of 18S rRNA,
determined by a premixed assay on demand for human 18S rRNA
(PE Biosystems, Darmstadt, Germany). For 29 samples BMPR2
cDNA amplification failed and therefore, only 161 were included
in the study.
Sequencing of the BMPR2
Sequencing of the BMPR2 (13 exons, exon-intron boundaries;
NM_001204 in the NCBI GenBank; 1271 bp in the 59 region and
1282 bp in the 39 UTR) in 48 non-related Caucasian subjects (12
lean subjects with NGT, 12 visceral obese, 12 subcutaneously
obese, 12 with T2D) was performed using the Big Dye Terminator
(Applied Biosystems, Inc., Foster City, CA) on an automated DNA
capillary sequencer (ABI PRISM 3100 Avant; Applied Biosystems
Inc., Foster City, CA). Sequence information and PCR conditions
for all oligonucleotide primers used for variant screening are
available upon request.
Genotyping of BMPR2 SNPs
SNP genotyping was done using the TaqMan SNP Genotyping
assay according to the manufacturer’s protocol (Applied Biosys-
tems, Inc., Foster City, CA). To assess genotyping reproducibility,
a random ,5% selection of the sample was re-genotyped in all
SNPs; all genotypes matched initial designated genotypes. 48
samples used for sequencing were also re-genotyped by TaqMan
technique and perfectly matched the genotypes determined by
sequencing.
Statistical analyses
Prior to statistical analysis, non-normally distributed parameters
were ln-transformed to approximate a normal distribution.
Differences in genotype frequencies between the obese or diabetic
cases and healthy controls were compared using logistic regression
analyses. Multivariate linear relationships were assessed by
generalized linear regression models. All analyses were done
under the additive model and the presented P-values are adjusted
for age, sex (and BMI for glucose traits). Differences in mRNA
expression between visceral and subcutaneous adipose tissue were
assessed using the paired Student’s t-test.
Two-sided P-values ,0.05 were considered to provide nominal
evidence for association and are presented without correction for
multiple hypothesis testing. The analysis of associations with
quantitative traits was restricted to non-diabetics to avoid diabetes
status or treatment masking potential effects of the variants on
these phenotypic traits.
To obtain the combined effect of our two cohorts we performed
a meta-analysis by using the METAL software [30]. The meta-
analysis was performed in a fixed effects model by using the
Mantel-Haenszel method. In haplotype analyses, groups of
subjects carrying 2, 1, or 0 copies of the haplotype were compared.
To estimate haplotypes the PHASE version 2.1 software was used
[27;31]. The phase reconstruction method considers the unknown
Figure 1. Site class probability bar plot for each codon across the BMPR2 sequence indicating strength of conservation at each
amino acid position. The degree of negative selection is equivalent to the strength of conservation. Included are 36 vertebrate orthologs. Human
sequence was used as reference. Genetic domains above are annotated according to http://www.uniprot.org/uniprot/Q13873. Numbers represent
the location of the domains (amino acids).
doi:10.1371/journal.pone.0016155.g001
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16155Figure 2. BMPR2 mRNA expression in visceral (Vis) and subcutaneous (SC) adipose tissue in lean, obese and type 2 diabetic
subjects. The data are means 6SEM; BMPR2 mRNA levels in (A) men (N=80) and women (N=81), (B) subgroups of lean (BMI ,25 kg/m
2; N=44),
overweight (25 kg/m
2 , BMI ,30 kg/m
2; N=37), SC obese (N=57) and Vis obese (N=23) (BMI .30 kg/m
2); (C) subjects with normal glucose
tolerance (NGT; N=116) and with impaired glucose tolerance (IGT; N=15) or with type 2 diabetes (T2D; N=30). * and *** indicate statistical
significance at P,0.05 and P,0.001, respectively when compared with expression in lean subjects (Figure B) or in subjects with NGT (Figure C);
# indicates statistical significance for differences between fat depots (Vis vs. SC) for appropriate subject groups;
## and
### indicate statistically
significant at P,0.01 and P,0.001, respectively. AU, arbitrary units.
doi:10.1371/journal.pone.0016155.g002
BMPR2 and Obesity
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their conditional distribution in light of the genotype data.
Statistical analyses were performed using SPSS version 18
(SPSS, Inc.; Chicago, IL) and STATA (version 9.0), (StataCorp
LP, Texas, USA).
Results
Evolutionary analyses
The dN/dS analyses revealed that the BMPR2 is highly
conserved among the 36 species analysed (average v=0.1278;
Figure S1), hence being subjected to an overall purifying
selection. Positional analyses indicate that 53.6% of positions
are very strongly conserved, v=0.0037, 40.6% are strongly
conserved, v=0.1247, and 5.7% are conserved, v=0.9974
(Figure 1). Except for one, none of the SNPs shows striking
frequency differences between the observed populations as
indicated by the fixation index Fst (Fst,0.2). For rs4675278,
Fst-values indicate differences between European and East
Asian populations (European vs. Chinese Fst=0.2760, European
vs. Japanese Fst=0.3703), which is reflected in different allele
frequencies and a change of minor allele: CEU: 0.267 (A-
allele); CHB: 0.211 (G-allele); JPT: 0.136 (G-allele), YRI: 0.442
(A-allele).
The integrated haplotype score (iHS) is based on the
differential levels of linkage disequilibrium surrounding a
positively selected allele compared to the background allele at
the same position (Table S1) [5]. For the European population
iHS values below -2 were found for rs1980153 and rs16839127
(Table S1), i.e., haplotypes on the derived allele background are
longer compared to ancestral allele background. In contrast, for
rs6717924 the iHS was positive and nearly reached 2 in
Caucasians (iHS=1.986).
Figure 3. Correlations. A) between visceral (Vis) and subcutaneous (SC) BMPR2 mRNA expression; B) between Vis BMPR2 mRNA expression and %
body fat, C) between Vis BMPR2 mRNA expression and BMI, D) between SC BMPR2 mRNA expression and BMI. Data are ln-transformed to achieve
normal distribution.
doi:10.1371/journal.pone.0016155.g003
Table 1. Linear regression analyses of visceral (Vis) and
subcutaneous (SC) BMPR2 mRNA expression with
anthropometric and metabolic parameters (N=161).
Vis BMPR2 mRNA SC BMPR2 mRNA
R( P-value) R (P-value)
Age 0.275 (,0.001) 0.183 (0.020)
BMI 0.611 (,0.001) 0.320 (,0.001)
% body fat 0.611 (,0.001) 0.321 (,0.001)
WHR 0.540 (,0.001) 0.322 (,0.001)
Fasting plasma glucose 0.303 (,0.001) 0.259 (0.001)
Fasting plasma insulin 0.777 (,0.001) 0.499 (,0.001)
2-hr plasma glucose 0.419 (,0.001) 0.361 (,0.001)
GIR 20.815 (,0.001) 20.603 (,0.001)
GIR – glucose infusion rate during the steady state of the euglycemic-
hyperinsulinemic clamp.
doi:10.1371/journal.pone.0016155.t001
BMPR2 and Obesity
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obesity
Analysis of 161 paired samples of visceral and subcutaneous
adipose tissue showed significantly higher BMPR2 transcript levels
in subcutaneous compared with visceral fat, independent of
gender (Figure 2A). Even though the mRNA expression in men
tended to be higher than in women, the gender differences did not
reach statistical significance (Figure 2A). To investigate the ex-
pression according to bodyfat mass or fat distribution, weperformed
additional analyses in subgroups of lean (BMI,25 kg/m
2), over-
weight (25 kg/m
2,BMI,30 kg/m
2), and obese (BMI.30 kg/m
2)
subjects. Based on CT scans measurement (L4-L5) of abdominal
visceral and subcutaneous fat areas, obese subjects were further
categorized as predominantly visceral (Vis) or subcutaneous (SC)
obese as defined by a ratio of Vis/SC fat area .0.5 [19]. BMPR2
mRNA expression was significantly increased in both visceral and
subcutaneous adipose tissue of 37 overweight and 80 obese (57
subcutaneously obese and 23 visceral obese) compared with 44 lean
subjects (P,0.001) (Figure 2B). Interestingly, the difference in
BMPR2 mRNA expression between visceral and subcutaneous
adiposetissuewasonlyseeninleanindividuals,butnotinoverweight
or obese subjects (Figure 2B). We further asked whether impaired
glucose metabolism in patients with either IGT (N=15) or T2D
(N=30) may be associated with altered BMPR2 mRNA expression
in different fat depots. Subgroup analyses demonstrated that IGT
and T2D subjects were indistinguishable with regard to BMPR2
mRNA expression; therefore these groups were analysed together.
Patients with IGT/T2D had significantly higher BMPR2 mRNA
expression in both visceral and subcutaneous fat compared to NGT
(N=116) subjects (Figure 2C). We detected a significant correlation
between visceral and subcutaneous BMPR2 mRNA expression
(Figure 3A).
Correlation of BMPR2 mRNA expression with parameters
of obesity, glucose metabolism, and insulin sensitivity
Univariate regression analysis revealed significant positive
correlations between both Vis and SC BMPR2 mRNA expression
and BMI, % body fat, waist, WHR, fasting and 2-hr plasma
glucose, and fasting plasma insulin (Table 1; Figure 3). There was
an inverse correlation between Vis and SC BMPR1A mRNA
expression and glucose uptake during the steady state of a
euglycemic-hyperinsulinemic clamp (Table 1). The correlations
remained unchanged also after excluding subjects with IGT and
T2D (data not shown). The correlation between BMPR2 mRNA
expression in fat and glucose infusion rate during the steady state
of an euglycemic–hyperinsulinemic clamp remained significant
even upon adjusting for age, gender and % body fat (Table 2).
Genetic variation in the BMPR2
We sequenced the human BMPR2 in 48 DNA-samples and
found eight genetic variants (Figure 4). Further, ten HapMap
tagging SNPs, covering 100% of the variation in the BMPR2 locus
(according to HapMap Phase II; www.hapmap.org) [32], were
selected from the database using the Tagger software and the
following criteria: minor allele frequency (MAF).0.05 and
r
2.0.8. These SNPs were additionally genotyped in the 48
Table 2. Multivariate linear regression analyses of visceral
(Vis) and subcutaneous (SC) BMPR2 mRNA expression with
anthropometric and metabolic parameters (N=161).
Vis BMPR2 mRNA SC BMPR2 mRNA
b-Coefficient (P-value) b-Coefficient (P-value)
Model 1
Age (years) 0.049 (0.0004) 0.028 (0.021)
Gender 20.010 (0.980) 0.030 (0.935)
Model 2
Age (years) 0.025 (0.029) 0.017 (0.142)
Gender 0.010 (0.977) 0.032 (0.926)
BMI 6.792 (,0.001) 2.916 (,0.001)
Model 3
Age (years) 0.030 (0.010) 0.019 (0.103)
Gender 20.045 (0.893) 0.008 (0.981)
% body fat 4.710 (,0.001) 2.044 (,0.001)
Model 4
Age (years) 0.011 (0.179) 0.005 (0.659)
Gender 20.109 (0.663) 0.004 (0.990)
% body fat 2.325 (,0.001) 0.154 (0.771)
GIR 22.898 (,0.001) 22.047 (,0.001)
Model 1: correlation with age and gender as predictors of obesity;
Model 2: with BMI as measure of obesity and 3 with % fat as measure of obesity:
test whether correlation between BMPR2 mRNA expression and obesity
withstands adjustments for age and gender;
Model 4: test whether correlation between the BMPR2 mRNA expression and
GIR is independent of obesity.
doi:10.1371/journal.pone.0016155.t002
Figure 4. Genetic structure and SNPs analysed in the bone morphogenetic receptor 2 gene (BMPR2). The polymorphisms shown in black
were discovered by direct gene sequencing. One of them was novel (w/o rs-number). Ten HapMap tagging polymorphisms (shown in grey) were
analysed for association with obesity and related phenotypes in German subjects.
doi:10.1371/journal.pone.0016155.g004
BMPR2 and Obesity
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16155DNA-samples. We calculated the linkage disequilibrium (L.D.)
between all SNPs using the EMLD statistical program (https://
epi.mdanderson.org/qhuang/Software/pub.htm) (Table S2). Based
on L.D., all SNPs identified through sequencing and with a minor
allele MAF.0.05 were represented by at least one HapMap tagging
SNP (L.D. with r
2.0.8) (Table S2). Since two HapMap tagging
SNPs were in 100% L.D. in our population (rs13426118 and
rs1061157), only 9 tagging SNPs were therefore taken forward to
genotyping for association studies in German Caucasians (Leipzig).
For replication analyses we included the Sorbs from Germany. All
SNPs were in Hardy-Weinberg equilibrium (P.0.05).
BMPR2 variants and association with obesity
Leipzig cohort. In a case-control study including 447 lean
(BMI,25 kg/m
2) and 701 obese (BMI.30 kg/m
2) subjects,
rs6717924 and rs13426118 were nominally associated with
obesity (P,0.05, adjusted for age and sex). Carriers of the minor
allele for rs6717924 were at higher risk of being obese (odds ratio
(OR) and [95% CI] = 1.40 [1.06; 1.85], P=0.018) whereas
subjects with the minor allele for rs13426118 were protected
against obesity (0.71 [0.55; 0.93], P=0.013 in an additive mode of
inheritance after adjusting for age and sex) (Table 3, Table S3).
Sorbs. The two SNPs nominally associated with obesity in
the Leipzig cohort were genotyped in the Sorbs for replication.
None of the SNPs showed significant association in the Sorbs
case-control study (337 lean and 215 obese subjects) (Table 3,
Table S3).
In a combined analysis including both the Sorbs and the Leipzig
cohort, only rs6717924 showed association with obesity (combined
OR and CI- 1.35 [1.07; 1.70]; P=0.011) (Table 3). The combined
effects of the SNPs on obesity were confirmed in a meta-analysis
using the metan command in STATA based on the estimated
effect sizes of each study and their confidence intervals. The allele/
genotype frequencies in the phenotypic groups (lean vs. obese)
remained unchanged also after excluding subjects with T2D.
However, due to smaller sample size, P-values did not reach
statistical significance (data not shown).
BMPR2 variants and association with obesity related
quantitative traits
Leipzig cohort. Consistentwith case-controlstudies,wefound
nominal associations between rs13426118 and BMI in 900 subjects
without T2D. As expected, carriers of the obesity risk allele (major)
had a higher mean BMI (Table 4) than the non-carriers.
In addition, rs1980153 showed effects on adiponectin,
rs4303700 on % body fat, rs12621870 on fasting plasma insulin,
and rs17199235 on 2-hr plasma glucose levels (Table 4).
We also assessed the association of the nine SNPs with T2D in a
case-control study including 930 cases with T2D and 722 healthy
controls with NGT from the Leipzig cohort. No significant
association with T2D was found under logistic regression analysis
(P.0.05; adjusted for age, sex and BMI; data not shown).
Sorbs. The two SNPs (rs13426118, rs6717924) nominally
associated with obesity in a case-control study in the Leipzig
cohort, were also tested for associations with BMI and obesity
related traits in 819 non-diabetic Sorbs. Although rs13426118 was
nominally associated with BMI (P,0.05, adjusted for age and sex;
Table 4), it showed opposite effect direction when compared with
the Leipzig cohort. Moreover, rs6717924 was associated with
fasting plasma insulin and 2-hr plasma insulin (P,0.05, adjusted
for age, sex and BMI).
Combined P-values of the two BMPR2 SNPs in our two study
cohorts were assessed by a meta-analysis using the METAL
software. Both SNPs, rs6717924 and rs13426118, showed nominal
significant association with fasting plasma insulin (P=0.022, and
P=0.044 respectively).
Haplotype analyses in the Leipzig cohort
Using the PHASE version 2.1 software [27;31], we identified nine
common haplotypes (frequency of each haplotype $0.05 among the
ten BMPR2 tagging SNPs. A summary of the haplotypes is given in
Table S4. These nine haplotypes accounted for .80% of allobserved
haplotypes, where haplotypes were defined by the composition of
alleles at each SNP in the following order: [rs6717924]-[rs1980153]-
[rs4303700]-[rs13426118]-[rs16839127]-[rs12693968]-[rs4675278]-
[rs12621870]-[rs17199235]-[rs1061157]. Three haplotypes were
significantly associated with obesity. The frequency of the haplotypes
[AAGAGAGTAG] and [GAGAGGATAG] were significantly
increased in the obese group (21.0% vs. 14.0% and 15.9% vs.
10.8% in the lean subjects) whereas the haplotype [GAGCGAG-
TAA] showed increased frequency in lean controls (18.8% vs. 13.3%
in the obese group) (P=0.006, P=0.006, and P=0.021; adjusted for
age and sex; heterozygote and homozygote haplotype carriers were
grouped together due to small sample size in the homozygote
haplotype carrier group). Furthermore, carriers of the haplotype
[GAGAGGATAG] had significantly higher 2-hr plasma glucose
levels and a lower glucose infusion rate compared to non-carriers
(P=0.011 and 0.026; adjusted for age, sex and BMI).
Association of rs6717924 with BMPR2 mRNA expression
Carriers of the rs6717924 A-allele (i.e. obesity risk allele) had
higher BMPR2 mRNA expression in visceral adipose tissue
compared to carriers of the non-risk alleles (P=0.042 adjusted
for age, sex and BMI; Figure 5; N=161). Consistent with the
analyses in the entire cohort, the rs6717924 obesity risk allele was
Table 3. Association analyses of the BMPR2 genetic variants with obesity in the Leipzig and the Sorbs cohorts.
Leipzig (a) n=1148 Sorbs (b) n=552 Combined analysis
Major
allele Minor allele
Minor allele
frequency
(Case/Control) OR [95% CI] P-value
Minor allele
frequency
(Case/Control) OR [95% CI] P-value OR [95% CI] P-value
rs6717924 G A 0.14/0.11 1.40 [1.06;1.85] 0.018 0.15/0.12 1.19 [0.77;1.84] 0.43 1.35 [1.07;1.70] 0.011
rs13426118 A C 0.11/0.15 0.71 [0.55;0.93] 0.013 0.13/0.11 1.22 [0.78;1.91] 0.39 0.93 [0.72;1.21] 0.61
OR [95%CI]; odds ratio with 95% confidence intervals; P-values were adjusted for age and sex.
*ORs indicate effect directions of the minor allele in additive mode of inheritance.
a) N=701 cases (BMI.30 kg/m
2) vs. 447 controls (BMI,25 kg/m
2), b) N=215 cases vs. 337 controls. Combined ORs and P-values represent the combined analysis of the
two cohorts (Leipzig and Sorbs). The combined analyses were adjusted for age, sex and study cohort.
doi:10.1371/journal.pone.0016155.t003
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Leipzig cohort (A) BMI WHR
Fasting
plasma
glucose
2-hr
glucose
OGTT
Fasting
plasma
insulin GIR % body fat Leptin Adiponectin
rs6717924 G.A
P-value 0.247 0.791 0.551 0.347 0.261 0.958 0.165 0.071 0.222
b 0.014 0.003 0.005 20.019 20.123 0.004 0.056 0.192 20.099
SE 0.012 0.012 0.008 0.020 0.109 0.085 0.040 0.106 0.081
rs1980153 A.T
P-value 0.666 0.470 0.204 0.226 0.430 0.554 0.739 0.688 0.019*
b 20.006 20.010 20.012 20.028 0.104 0.057 20.016 0.050 0.223
SE 0.014 0.014 0.009 0.023 0.132 0.097 0.047 0.124 0.094
rs4303700 G.A
P-value 0.206 0.743 0.470 0.768 0.103* 0.330 0.021* 0.976 0.691
b 20.012 20.003 20.005 20.005 0.140 20.063 20.075 0.003 20.027
SE 0.010 0.010 0.007 0.016 0.086 0.065 0.032 0.085 0.067
rs4675278 G.A
P-value 0.077# 0.966 0.529 0.661 0.338 0.827 0.728 0.177* 0.572
b 0.013 20.0003 0.003 20.005 20.061 0.011 0.008 20.085 20.027
SE 0.007 0.007 0.005 0.012 0.064 0.049 0.023 0.063 0.047
rs16839127 G.A
P-value 0.994 0.346 0.876 0.837 0.287# 0.823 0.641 0.639 0.742
b 20.0001 0.015 0.002 0.005 0.146 0.022 20.023 20.062 0.033
SE 0.016 0.016 0.010 0.025 0.137 0.100 0.049 0.133 0.101
rs12693968 G.A
P-value 0.413 0.285 0.563 0.476 0.426 0.691 0.158 0.113 0.324
b 20.008 20.011 0.004 20.012 20.070 20.027 0.045 0.134 20.063
SE 0.010 0.010 0.007 0.016 0.087 0.068 0.032 0.085 0.064
rs12621870 T.C
P-value 0.827 0.572 0.280 0.203* 0.025* 0.350 0.559 0.539 0.195
b 0.002 20.005 0.007 20.019 20.179 0.059 20.017 20.050 20.078
SE 0.009 0.009 0.006 0.015 0.080 0.063 0.028 0.082 0.060
rs17199235 A.G
P-value 0.745 0.744 0.570 0.042* 0.058* 0.111 0.642 0.487 0.526
b 0.004 0.004 0.004 20.037 20.190 0.131 20.017 0.074 20.049
SE 0.011 0.011 0.008 0.018 0.100 0.082 0.037 0.106 0.077
rs13426118 A.C
P-value 0.016* 0.222 0.939 0.774 0.319 0.588 0.923 0.413# 0.597
b 20.030 20.015 20.001 0.006 20.107 20.045 20.004 0.089 20.045
SE 0.012 0.012 0.008 0.020 0.107 0.083 0.042 0.109 0.085
Sorbian cohort (B) BMI WHR
Fasting
plasma
glucose
2-hr
glucose
OGTT
Fasting
plasma
insulin
2-hr
insulin p-Fat
rs6717924 G.A
P-value 0.924 0.438 0.998 0.261 0.033* 0.030* 0.545
b 0.001 20.007 ,0.001 20.025 20.084 20.140 0.018
SE 0.011 0.009 0.006 0.022 0.039 0.064 0.029
Combined P-value 0.366 0.731 0.665 0.145 0.022
rs13426118 A.C
P-value 0.018* 0.406 0.790 0.616 0.061 0.443 0.096
b 0.026 0.007 0.002 20.011 20.073 20.049 0.047
SE 0.011 0.008 0.006 0.022 0.039 0.064 0.028
Combined P-value 0.912 0.757 0.898 0.890 0.044
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sex and age). Including visceral BMPR2 mRNA expression as a
covariate abolished the SNP effect on BMI (P=0.31) while the
effect on mRNA expression remained significant (P,0.001). None
of the other SNPs was associated with either visceral or
subcutaneous BMPR2 mRNA expression.
Discussion
BMPR2 plays an important role during embryonic develop-
ment and remains ubiquitously expressed in later life. Employing
genome wide screening strategies, the BMPR2 locus has been
suggested to be a target of recent evolutionary selection in human
populations [5]. So far, genetic variants in the BMPR2 have been
described to be responsible for the majority of cases of the
autosomal hereditable pulmonary arterial hypertension [33].
Functional studies revealed that vascular BMPR2 mRNA expres-
sion is up-regulated in early stages of autoimmune diabetes in non-
obese diabetic mice [34] and improved renal bone morphogenetic
protein 7 (BMP7) and BMPR2 mRNA expression following
treatment in streptozotocin-induced diabetic rats is of benefit
against renal damage during diabetic nephropathy [35]. However,
little is known about the role of BMPR2 in the pathophysiology of
human obesity despite evidence for involvement of BMPs in the
regulation of adipogenesis [9]. Also our recent studies on
BMPR1A, partner in the receptor complex with BMPR2, suggest
a regulatory role of these receptors in obesity [18]. We therefore
performed a systematic study on the potential role of BMPR2 in
the pathophysiology of obesity by combining data from genetic,
evolutionary, phenotypic and adipose tissue expression studies.
We analysed the coding region of 36 vertebrate BMPR2
orthologs to screen for signatures of selections between species
and showed that BMPR2 has undergone an overall purifying
selection. Considering strong physiologic relevance of BMPR2 in
developmental processes, it is not surprising that the coding region
shows very strong conservation with more than half of amino acid
positions being very strongly conserved. To assess intronic regions,
we used Haplotter/PhaseII database to screen for selection
patterns within the BMPR2 locus. Population genetic measures
represented by high iHS in Caucasian populations (Table S1)
indicated signatures of recent selection at the BMPR2 locus.
Since BMPR2 is considered a plausible obesity candidate gene,
we investigated its role in the pathophysiology of human obesity.
We found significantly higher BMPR2 mRNA expression in fat in
overweight and obese compared to lean individuals. In addition,
BMPR2 mRNA expression was significantly higher in subjects with
IGT/T2DM compared to controls with NGT. BMPR2 mRNA
expression correlated with measures of obesity and fat distribution,
as well as with traits of glucose metabolism and insulin sensitivity.
Notably, the visceral BMPR2 expression increased remarkable in
the overweight subjects. Furthermore, the difference in BMPR2
mRNA expression between the two fat depots with higher
expression in subcutaneous adipose tissue, predominantly in lean
individuals, might suggest involvement of BMPR2 in the
regulation of fat distribution. In such a case one would assume
different expression patterns between both fat depots when
comparing subcutaneously obese with viscerally obese patients.
However, despite the highest expression levels (in both fat depots)
found in viscerally obese patients, there were no depot differences
in any of the ‘‘obese’’ groups (overweight, SC and Vis obese).
Therefore, it seems that the depot differences observed in the total
cohort were due to significant differences found in lean but not
obese individuals. Correlations of BMPR2 expression with obesity
and relevant metabolic traits suggest that BMPR2 mRNA
expression in human adipose tissue might be related to progression
of obesity but it remains unclear whether it is due to the extended
fat mass or vice versa. Consistent with recent studies on BMPR1A
[18], positive correlation of BMPR2 mRNA expression with
obesity suggests that obese individuals may have enhanced BMP-
2/4 signalling, which may stimulate adipose tissue differentiation
thereby contributing to increased fat mass. However, based on
such correlation analyses, the direction of the causative chain can
not be established and we can therefore not exclude that increased
BMPR2 expression may be a consequence rather than the cause of
increased fat mass.
The genotype-phenotype association study showed two SNPs
(rs6717924, rs13426118) nominally associated with obesity in the
Leipzig cohort. However, they could not be replicated in the
Sorbs, even though combined analyses of both cohorts supported
the association of rs6717924 A-allele with obesity. Similarly,
association of BMPR2 SNPs with quantitative traits was moderate
and would not withstand adjustment for multiple testing (e.g.
Bonferroni correction). In a subgroup of 161 subjects the
rs6717924 obesity risk allele was associated with visceral BMPR2
Figure 5. Association of rs6717924 with adipose tissue BMPR2
mRNA expression. Given are means6SEM. A minor allele; G major
allele.
doi:10.1371/journal.pone.0016155.g005
The dataset included subjects with NGT and IGT (N=900, except for % body fat, leptin and adiponectin (N=374) for the Leipzig cohort; N=819 for the Sorbs cohort). P-
values were calculated after adjusting for age and gender for the variables BMI, WHR and % body fat; and for age, gender and BMI for the remaining variables. b indicate
effect directions of the minor alleles. P-values are given for the additive model.
*/# significant in dominant/recessive mode of inheritance; dominant model indicates Mm+mm vs. MM; BMI=body mass index; WHR=waist-to-hip ratio; OGTT=oral
glucose tolerance test; GIR=glucose infusion rate.
doi:10.1371/journal.pone.0016155.t004
Table 4. Cont.
BMPR2 and Obesity
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16155mRNA expression and BMI. Including visceral BMPR2 mRNA
expression as a covariate abolished the SNP effect on BMI while
the effect of mRNA expression levels remained significant. This
suggests that the moderate SNP effect on BMI might be mediated
through its effect on the visceral BMPR2 mRNA expression level.
Altered BMPR2 mRNA expression might result in changes in
adipose tissue expansion during the activation of division and
differentiation of adipocyte precursor cells. Undoubtedly, studies
targeting functional consequences of BMPR2 obesity risk variants
on BMPR2 transcription are inevitable to clarify whether genetic
variants can explain variation in BMPR2 mRNA expression.
Nevertheless, the iHS value of nearly 2 for the rs6717924 suggests
that the haplotypes on the background of the ancestral allele A,
which was associated with obesity and visceral mRNA levels, are
longer compared to derived allele background and thus subject to
recent positive selection.
Taking higher BMPR2 mRNA levels in carriers of the
rs6717924 A-allele into account, we used the Transcription
Element Search System (TESS; http://www.cbil.upenn.edu/tess)
to examine transcriptional binding sites surrounding this genetic
variant, which might explain variation in BMPR2 expression. The
sequence surrounding rs6717924 (G.A) matches human tran-
scription binding site for a transcription factor IPF1 (insulin
upstream/promoter factor 1) for the G-allele. IPF1 is needed for
the formation of the pancreas and is assumed to determine the fate
of common pancreatic precursor cells and/or to regulate their
propagation [36]. In this regard, it seems noteworthy that we
observed nominal association of the rs6717924 with fasting plasma
insulin levels in a combined analysis of both cohorts. Moreover,
there is evidence that BMPs might regulate insulin secretion.
BMP4 and its high-affinity receptor BMPR1A are expressed in
differentiating and adult beta cells and transgenic expression of
Bmp4 in mice beta cells enhances glucose stimulated insulin
secretion and glucose clearance [37]. Although BMPR2 expression
was higher in subjects with T2D, the genetic variation in BMPR2
does not appear to be a major player in the polygenic aetiology of
T2D as no association of genetic polymorphisms with T2D was
found.
We are aware that statistical power of our study is limited due to
relatively small sample size. In our cohorts we had a power of 80%
(a=0.05) to detect a difference of 0.7121.32 kg/m
2 per allele for
BMI, 0.0820.15 mmol/l for fasting plasma glucose, 3.942
18.07 pmol/l for fasting plasma insulin, 0.2320.43 mmol/l for 2-
hr glucose during an OGTT under the additive model. Similarly, in
the case control studies for obesity, we had a power of 80% (a=0.05)
to detect SNP effects with odds ratios (ORs)ranging from 1.21 to 1.44
andfrom1.35to1.37intheLeipzigandSorbs,respectively.Sincethe
reported effect sizes for obesity SNPs are usually lower (ORs of 1.1–
1.2), smaller effect may have been missed in our studies.
In conclusion, our data on expression, genetics as well as
evolutionary aspects suggest a role of BMPR2 in the pathophys-
iology of obesity and provide some evidence for thrifty genotype
hypothesis.
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Figure S1 Phylogeny for BMPR2 with estimates of v for
each species (A) and list of species analysed (B). v-values
were obtained under the ‘‘free-ratio’’ model. C.=Common, N.=
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Table S3 Association of BMPR2 genetic variants with
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vs. 701 obese subjects (BMI.30 kg/m
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after adjusting for age and gender. Odds ratios (OR) and 95%
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